reports
- Wim Hoste
Recticel Feedback conference call
Below are the highlights of the conference call. FY25 adjusted EBITDA increased by 12.5% and was in line with our forecasts while being 4% above consensus. Although expecting continued volume growth in 2026, Recticel does not provide a guidance at this stage, citing ao input cost volatility. CEO Jan Vergote will become Executive Chairman, while the current CEO of Recticel's Insulation Boards division, Stefaan Debusschere, will become new group CEO. Recticel still has significant firepower for ad...
- Ahmed Ben Salem
LHN HOLCIM AG
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
ENGI ENGIE SA.
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
GRF GRIFOLS S.A. CLASS A
BAS BASF SE
BCP BANCO COMERCIAL PORTUGUES S.A.
UCB UCB S.A.
WPP WPP PLC
ANA ACCIONA SA
ACKB ACKERMANS & VAN HAAREN NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
KGX KION GROUP AG
IBE IBERDROLA SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
SAN BANCO SANTANDER S.A.
GRF.P GRIFOLS S.A. PREF CLASS B
DHER DELIVERY HERO SE
BIM BIOMERIEUX SA
STLA STELLANTIS N.V.
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
STMN STRAUMANN HOLDING AG
H2O HIDROELECTRICA S.A.
- Ahmed Ben Salem
LHN HOLCIM AG
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
ENGI ENGIE SA.
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
GRF GRIFOLS S.A. CLASS A
BAS BASF SE
BCP BANCO COMERCIAL PORTUGUES S.A.
UCB UCB S.A.
WPP WPP PLC
ANA ACCIONA SA
ACKB ACKERMANS & VAN HAAREN NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
KGX KION GROUP AG
IBE IBERDROLA SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
SAN BANCO SANTANDER S.A.
GRF.P GRIFOLS S.A. PREF CLASS B
DHER DELIVERY HERO SE
BIM BIOMERIEUX SA
STLA STELLANTIS N.V.
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
STMN STRAUMANN HOLDING AG
H2O HIDROELECTRICA S.A.
- Thijs Berkelder
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative
- Thijs Berkelder
- Wim Hoste
Fugro FIRST LOOK: weak 4Q, comforting offshore wind comments, savings ...
FY Adj.EBIT landed at €90.9m, below our estimate (€96m) and above consensus (€84m). Resulting margin is at 4.9% (vs. our 5.2% E). Backlog for the next 12m stands at € 1396m (-5.7% comp y/y). Full year revenues were mainly derived from Oil&Gas (45%, -2% y/y) and Renewables (26%, -40% y/y). Leverage remains under control at 1.4x. As foreseen no quantitative guidance on 2026 was issued. Positive is that the savings ambition is revised to the upper end of the previous € 100-120m guidance whilst we a...
- Guy Sips
- Hilde Van Boxstael
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Russell Waller
Proximus (Neutral, TP: €8.3, +0%) Q4 25 and CMD Quick Take: Dividend ...
Proximus is holding a CMD in Brussels today that we are attending. Ahead of that, it has put out a release with FY26, FY28 guidance, and some long-term (FY30) capex and FCF estimates too. We don’t have all the detail yet, but we outline our initial thoughts in this report, and some commentary on the Q4 results too.
- Michiel Declercq
Proximus Targeting € 400m FCF by 2030, dividend cut in FY26
Proximus reported solid 4Q25 results, with the underlying EBITDA of € 437m broadly in line with expectations (kbcse: € 433m, css: € 434m) while the FY25 organic FCF of € 130m came in slightly ahead (kbcse: € 107m, css: € 102m). Although the outlook 2026 was broadly in line, we welcome the lower capex spending of between € 1.20- € 1.25bn (kbcse: € 1.30bn, css: € 1.29bn), resulting in a better than expected FCF guidance for 2026 of up to € 100m (kbcse: € 39m, css: € 24m). By 2030, the group expect...
- Guy Sips
Materialise A Two-Speed Story
Materialise enters 2026 with diverging momentum across its business segments: - Medical continues to expand robustly, increasingly becoming the company's structural growth engine driven by deeper platform adoption and mass personalization. - Software is transitioning successfully toward a subscription-based, cloud-native AM workflow platform, with significant medium-term operating leverage. - Manufacturing faces persistent macro softness, particularly in European prototyping, with recovery depen...
- Wim Hoste
Recticel FIRST LOOK: FY25 adj. EBITDA +12.5%; no guidance; CEO transit...
FY25 adjusted EBITDA increased by 12.5% and was in line with our forecasts while being 4% above consensus. Although expecting continued volume growth in 2026, Recticel does not provide a guidance at this stage, citing ao input cost volatility. CEO Jan Vergote will become Executive Chairman, while the current CEO of Recticel's Insulation Boards division, Stefaan Debusschere, will become new group CEO. Recticel still has significant firepower for additional acquisitions and we would expect the com...
- Mathijs Geerts Danau
mdxhealth FY25 revenues slightly below preliminary figures but guidanc...
mdxhealth's 4Q25 revenues come in $ 1m lower than the preliminary revenue figures shared in January ($ 30.5m). However the company maintains FY26 revenue guidance of $ 137-140m, implying 27-30% year-over-year revenue growth in FY26. Management also reiterated expectations for continued operating leverage, with a limited increase in OPEX despite significant revenue growth. As a result, mdxhealth expects to achieve a 10% adj. EBITDA run-rate by YE26. We reiterate our BUY and $ 6 TP.
Ackermans & van Haaren ends a successful year 2025 with a net profit o...
Ackermans & van Haaren ends a successful year 2025 with a net profit of 593 million euros (+29%) Dear shareholder, Dear Madam, Dear Sir, Please find attached our press release with the FY2025 Results: Outstanding results at DEME, Delen Private Bank, Bank Van Breda and SIPEF boost net profit to 592.5 million euros.Equity strengthens to 5.7 billion euros, delivering a 10.3% return on equityProposal to increase the dividend to 4.60 euros per share (+21%) Best regards Ackermans & van Haaren Attachment
Ackermans & van Haaren clôture un excellent exercice 2025 avec un béné...
Ackermans & van Haaren clôture un excellent exercice 2025 avec un bénéfice net de 593 millions d'euros (+29%) Cher actionnaire, Monsieur, Madame, Veuillez trouver ci-joint notre communiqué concernant nos résultats annuels 2025: Les excellents résultats de DEME, Delen Private Bank, la Banque Van Breda et SIPEF propulsent le bénéfice net à 592,5 millions d'eurosLes fonds propres se renforcent à 5,7 milliards d'euros, générant ainsi un rendement des fonds propres de 10,3 %.Proposition d'augmenter le dividende à 4,60 euros par action (+21%) Meilleures salutations, Ackermans & van Haare...
Ackermans & van Haaren sluit een succesvol jaar af met een nettowinst ...
Ackermans & van Haaren sluit een succesvol jaar af met een nettowinst van 593 miljoen euro (+29%) Geachte aandeelhouder, Geachte mevrouw, geachte heer, Gelieve bijgevoegd ons persbericht over de jaarresultaten 2025 te vinden. Uitmuntende resultaten bij DEME, Delen Private Bank, Bank Van Breda en SIPEF stuwen de nettowinst naar 592,5 miljoen euroEigen vermogen versterkt tot 5,7 miljard euro, waardoor AvH 10,3% rendement op eigen vermogen levertVoorstel om het dividend te verhogen tot 4,60 euro per aandeel (+21%) Met vriendelijke groeten, Ackermans & van Haaren Bijlage ...
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Result...
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, comme...
Fagron completes strategic acquisition of Pharmavit Europe, strengthen...
Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw material...
Fagron voltooit strategische overname van Pharmavit Europe en versterk...
Fagron voltooit strategische overname van Pharmavit Europe en versterkt daarmee haar leiderschap in snelgroeiende nutraceutische ingrediënten in EMEA Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 26 februari 2026 – 18:30 Fagron voltooit strategische overname van Pharmavit Europe en versterkt daarmee haar leiderschap in snelgroeiende nutraceutische ingrediënten in EMEA Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, kondigt de afronding aan van de overname van Pharmavit Europe, een toonaangevende Europese distributeur van ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.